The Prenatal Hormone Milieu in Autism Spectrum Disorder

Whitney Worsham 1*, Susan Dalton 2 and Deborah A. Bilder 3

1 University of Utah School of Medicine, Salt Lake City, UT, United States, 2 Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT, United States, 3 Division of Child & Adolescent Psychiatry, Department of Psychiatry, University of Utah, Salt Lake City, UT, United States

Though the etiology of autism spectrum disorder (ASD) remains largely unknown, recent findings suggest that hormone dysregulation within the prenatal environment, in conjunction with genetic factors, may alter fetal neurodevelopment. Early emphasis has been placed on the potential role of in utero exposure to androgens, particularly testosterone, to theorize ASD as the manifestation of an “extreme male brain.” The relationship between autism risk and obstetric conditions associated with inflammation and steroid dysregulation merits a much broader understanding of the in utero steroid environment and its potential influence on fetal neuroendocrine development. The exploration of hormone dysregulation in the prenatal environment and ASD development builds upon prior research publishing associations with obstetric conditions and ASD risk. The insight gained may be applied to the development of chronic adult metabolic diseases that share prenatal risk factors with ASD. Future research directions will also be discussed.

Keywords: autism, autism spectrum disorders, steroid hormone (progesterone, testosterone, estradiol), perinatal, prenatal, risk factors

INTRODUCTION

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social interaction and communication in addition to stereotyped, repetitive behaviors (1). While the etiology of ASD remains largely unknown, multifactorial contributors such as genetics, neuroanatomical abnormalities, and the environment likely play a role (2). Prenatal factors associated with elevated ASD risk include maternal conditions that contribute to a suboptimal prenatal environment, particularly as it relates to inflammation, metabolism, and steroid hormone regulation (3, 4).

Prenatal stress (5, 6), maternal immune dysfunction (5, 7–9), pre-existing/gestational diabetes (3, 10), pre-pregnancy obesity (11), weight gain during pregnancy (12), pre-existing/gestational hypertension (13, 14), polycystic ovarian syndrome (PCOS) (4, 15) and prenatal complications such as low birth weight (3) and pre-term birth (16) have all been associated with ASD in offspring. However, these conditions may alter prenatal mechanisms promoting ASD pathogenesis has yet to be clearly established, though several physiological processes that link these conditions have been implicated including direct insults (e.g., oxidative stress, hypoxia, inflammation) and adaptive responses (e.g., epigenetic changes, fetal programming) (17–20).

Studying the relevance of prenatal risk factors in ASD pathogenesis inherently involves understanding the remarkable, well-coordinated interaction among the mother, fetus, and placenta—referred to as the maternofetoplacental unit (21, 22). The interdependence across the maternofetoplacental unit for steroid hormone production, immune response mediation, and
nutrient transfer is particularly relevant to sustain pregnancy and ensure newborn viability. The placenta, together with the amnion and chorion, create a unique immune environment that permits co-existence of the fetal allograft within the mother while accessing her rich nutrient and oxygen supply for development, growth, and survival.

Immune response and steroid production are intrinsically linked during pregnancy with the placenta acting as the key mediator, particularly regarding estradiol and progesterone synthesis. Estradiol augments both cell- and antibody-mediated immune responses (23). Rising levels of estradiol during pregnancy promote an immunologic shift from an inflammatory state to a regulatory response (23–26). The dramatic increases in progesterone enhance maternal-fetal tolerance (27) and promote anti-inflammatory factors through progesterone-induced binding factor (PIBF) (28, 29). Placental progesterone, estradiol, and human chorionic gonadotropin (hCG) facilitate blastocyst implantation and spiral artery formation, which are essential early gestational events to sustain pregnancy. These hormones support implantation by recruiting immune cells to the maternal-fetal interface (30–33). Immune cells subsequently secrete angiogenic factors such as transforming growth factor beta (TGF-β) and vascular endothelial growth factor (VEGF) (31) to promote spiral artery formation (34) and placental vascularization.

The influence that placental steroid hormone production exerts across the maternalfetoplacental unit—involving inflammatory responses, oxygen/nutrient exchange, and neuroendocrine functioning—cannot be overstated. This review article will describe the current understanding of the in utero steroid-related environment associated with ASD and explore its potential role in ASD pathogenesis. Existing literature that is relevant to the prenatal hormone milieu in ASD largely appears to fall within the following four domains: obstetric conditions, fetal programming, sex differential, and steroid-related biomarkers. The literature on each domain will be summarized.

OBSTETRIC CONDITIONS

Hypertensive Disorders

Hypertensive disorders during pregnancy, regardless of subset (i.e., chronic, gestational, de novo or superimposed preeclampsia), have been correlated with elevated ASD incidence among offspring (13, 14, 35–37). Placental insufficiency is one of the most concerning complications of hypertension during pregnancy (22, 38, 39). Common indicators or complications of placental insufficiency that overlap with ASD risk factors include small for gestational age/in utero growth restriction, prematurity, maternal infection, and maternal metabolic syndrome (16, 38–42). Histologic signs of placental insufficiency, such as trophoblastic inclusions, are also more commonly found in placentas of children who develop ASD (43). Steroid hormone dysregulation, altered immune function, and placental insufficiency are intertwined, as maternal serum inflammatory markers (e.g., atypical cytokine profiles, leukocytosis, and elevated platelet counts) are associated with gestational hypertension (44), while the maternal cardiovascular adaption to pregnancy is influenced by placental estrogen and progesterone production (45).

Gestational Diabetes/Insulin Resistance

Maternal diabetes, both pre-existing and gestational onset, is also an established ASD risk factor (46, 47). While the exact mechanism underlying the relationship between ASD and maternal diabetes is unknown, maternal diabetes can lead to several obstetric complications affecting the mother (e.g., gestational hypertension, pre-eclampsia) and baby (e.g., high or low birth weight, shoulder dystocia, hypoglycemia, hyperbilirubinemia, hypocalcemia, and respiratory distress) (48, 49). These conditions result from the amplification of the typical prenatal metabolic state characterized by hypercortisolemia (50) and insulin resistance (51, 52). During uncomplicated pregnancies, relative maternal hypercortisolemia and insulin resistance facilitate adequate transfer of nutritional resources from mother to baby. As pregnancy progresses, a developmental switch prompted by rising fetal cortisol synthesis shifts resource allocation from tissue proliferation to maturation (53). In maternal diabetes, excess glucose supply to the fetus causes higher fetal insulin production to maintain glucose homeostasis, stimulating fetal overgrowth and delaying lung maturation (54). Diabetes during pregnancy also leads to higher placental release of pro-inflammatory cytokines (e.g., leptin, tumor necrosis factor-α (TGF-α), and interleukins) (55), with the potential consequence of reducing oxygen diffusion across the placenta by enhancing placental thickening (48).

Pre-pregnancy Obesity/Gestational Weight Gain

Epidemiologic studies identify increased ASD risk associated with pre-pregnancy obesity (46) and/or gestational weight gain (2, 12, 56). Obesity promotes both inflammation and endocrine dysfunction, perturbing the prenatal environment. As a pro-inflammatory state, obesity contributes to elevated lipids, leptin, and IL-6 during pregnancy (57). The bioavailability and synthesis of estrogens are impacted through the endocrine and metabolic function of adipose tissue (58). Furthermore, studies exploring the in utero steroid environment, primarily as it relates to hormone-sensitive cancer risk among offspring, have found elevated maternal serum estrogen, progesterone, and testosterone levels in pregnancies characterized by higher weight gain (58–61). Because the gestational weight gain associated with increased ASD risk (12) is not clinically relevant from an obstetric perspective (i.e., about three pounds), its link with ASD may relate to a shared etiology rather than a cause and effect relationship.

Maternal Stress

Epidemiologic studies have also found that heightened maternal stress during the 2nd trimester increases fetal vulnerability to adverse outcomes such as shortened gestational age, preterm birth, low birth weight, and small for gestational age (62). ASD has also been associated with intense maternal stress (e.g., life events and hurricanes) during this gestational window (5, 6, 63).
FETAL PROGRAMMING

Fetal programming, a concept also referred to as the "developmental origins of health and disease" hypothesis, explains that in utero disruption during critical developmental periods can relay health consequences to the fetus that persist throughout adulthood (64–68). Originally bolstered by epidemiological findings describing regional overlap in areas with high infant mortality and coronary heart disease (69), there has been increased recognition that in utero phenomena can lead to a wide range of chronic conditions. Supporting evidence includes the well-established relationship between prenatal exposure to maternal metabolic conditions [e.g., hypertension (70), diabetes (71–73), obesity (74–76)] and chronic metabolic disorders that begin in adolescence and adulthood (77, 78). Pre-pregnancy maternal obesity has been linked to poorer metabolic, endocrine, cardiovascular, and neurodevelopmental outcomes in offspring (79). Even after adjusting for pre-pregnancy obesity, maternal metabolic conditions such as gestational diabetes remain associated with increased risk of cardiovascular disease (80), obesity (81), type 2 diabetes (82), and early childhood metabolic syndrome development (83) among offspring.

Fetal programming of adolescent/adult metabolic disorders may occur through epigenetic changes (84). Telomeres are repetitive DNA tracts that protect against excessive chromosomal degradation (85). Shortened telomeres occur in fetuses exposed to gestational diabetes and are associated with higher cardiometabolic risk in adults (86, 87). Pre-eclampsia has been shown to induce epigenetic changes in offspring through decreased DNA methylation of IGF2 (88), a mediator of cell proliferation and apoptosis (89). Aside from its influence on postnatal growth, aberrant IGF2 expression is linked to subsequent development of hypertension, diabetes, and other metabolic disorders (88).

The proposed basis for fetal programming includes calibration of fetal regulatory systems in response to intrauterine nutrient availability to optimize extra-uterine survival. The subsequent mismatch between pre- and postnatal resources—whether involving excess or scarcity—predisposes offspring to develop one or more metabolic disorders. Fetal programming serves as a potential mechanism through which stress, metabolic disturbances, inflammation, and steroid dysregulation during pregnancy could predispose offspring to ASD. Altered fetal hypothalamic-pituitary-adrenal (HPA) axis development falls within the concept of fetal programming (90–92).

HPA Axis Functioning in ASD

The HPA axis modulates neural, endocrine, and immune responses to stress to maintain homeostasis (93). While HPA axis plays a critical role in coordinating short-term physiological stress responses (94), HPA axis dysregulation has been implicated in several psychological and physiological disorders (95–100). Some children with ASD demonstrate signs of HPA axis dysregulation (101–106) such as altered circadian rhythms (107) and abnormal cortisol stress responses (105). Collectively, these findings raise the possibility that aberrant HPA axis functioning in some ASD individuals may have originated during fetal life through fetal programming.

Fetal HPA Axis Maturation

Understanding fetal HPA axis development in the 2nd trimester (i.e., 13th to 26th week gestation) provides a context in which to interpret the association between ASD and steroid hormone levels (whether measured in maternal serum or amniotic fluid) during this gestational window. By the 12th week of gestation, the fetal hypothalamus releases corticotropin-releasing hormone (CRH) to signal the anterior pituitary gland to release adrenocorticotropic hormone (ACTH) (108–110). ACTH stimulates the fetal zone of the adrenal gland to synthesize dehydroepiandrosterone (DHEA) (110) and its conjugated form, dehydroepiandrosterone sulfate (DHEAS) (111). Although the fetal HPA axis is active by 12–18 weeks gestation (112), fetal adrenal gland development lags behind that of the hypothalamus and anterior pituitary. The fetal adrenal gland does not typically develop de novo cortisol synthesis capacity—referred to as fetal HPA axis maturation—until around 23–24 weeks gestation (91, 113–115). Because cortisol promotes the physiologic shift from somatic growth to organ maturation [e.g., lungs (116), gut (117), liver (116, 118)], fetal HPA axis maturation is essential for extra-uterine survival (119). Under duress, fetal HPA axis maturation can occur as early as 20 weeks gestation (113). This may be induced by increased placenta estradiol production (120).

The Placenta's Role in Fetal HPA Axis Maturation

Placental estradiol synthesis promotes fetal HPA axis maturation through multiple mechanisms. Estradiol influences cortisol transfer from the mother to fetus to establish a maternal-fetal cortisol gradient through its actions on placental 11β-hydroxysteroid dehydrogenase (11β-HSD) activity (121). 11β-HSD converts active maternal cortisol into inert cortisone. This gradient serves to protect the fetus from maternal cortisol overexposure (122, 123). Maternal cortisol in the fetal compartment exerts negative feedback on the fetal hypothalamus and anterior pituitary gland. As pregnancy progresses, 11β-HSD activity increases, less maternal cortisol reaches the fetal compartment, and negative feedback to the fetal HPA axis is reduced (115, 122, 124–126). The subsequent increase in fetal HPA axis activation coincides with the emergence of the fetal adrenals’ de novo cortisol synthesis capacity (125) leading to fetal HPA axis maturation (see Figure 1). The placenta synthesizes estradiol from its precursor DHEA(S) which is derived from both fetal and maternal adrenal glands (124, 140). Excess fetal DHEA(S) supply can drive increased placental estradiol synthesis (110, 124, 141, 142). Because the placenta shunts over 90% of the estradiol it produces into the maternal circulation, maternal serum estradiol levels reflect placental estradiol synthesis (130).

The placenta also influences fetal HPA axis maturation through its production of CRH (pCRH). pCRH stimulates fetal adrenal DHEA(S) production by (1) signaling fetal pituitary ACTH release (143), (2) heightening fetal adrenal gland sensitivity to ACTH (144), and (3) stimulating DHEA(S) producing fetal adrenal cells directly (145, 146). By increasing
FIGURE 1 | Placental estradiol and the fetal HPA axis at mid-gestation. (A) Normal fetal HPA axis functioning in the setting of typical placental estradiol activity at mid-gestation. (A) Depicts normal suppression of fetal HPA axis activity during mid-gestation by maternal cortisol. The placental glucocorticoid barrier contains (Continued)
fetal DHEA(S) synthesis, pCRH facilitates increased placental estradiol production. As estradiol acts on placental barrier enzymes that modulate fetal cortisol exposure, pCRH can indirectly facilitate precocious HPA axis maturation by decreasing negative feedback from maternal cortisol, pCRH also directly promotes adrenal de novo cortisol synthesis (147, 148). Following its maturation, activation of the fetal HPA axis signals adrenal production of both DHEA(S) and de novo cortisol.

**Inflammation and Hypoxia Stimulate Early Fetal HPA Axis Maturation**

Excess inflammation triggered by infection, tissue injury, autoimmunity, or disruption in immunogenic tolerance to the fetus (149) can provoke early fetal HPA axis maturation through increased fetal HPA axis activity (115). Likewise, hypoxia can also stimulate fetal HPA axis maturation through a similar mechanism (150). Considering estradiol's role in strengthening the maternal-fetal cortisol gradient, estradiol serves as a feasible intermediary through which inflammation and hypoxia contribute to precocious fetal HPA axis maturation.

Furthermore, pCRH synthesis is upregulated in response to signifiers of an adverse intrauterine environment, such as elevated cortisol levels, pro-inflammatory cytokines, catecholamines, and decreased uterine blood flow (115, 151, 152). As pCRH promotes ACTH release from the fetal pituitary gland (143) and expression of cortisol synthesizing enzymes (147), elevated pCRH from *in utero* stress can serve as an additional mechanism through which the fetal HPA axis matures precociously (153).

**Sex Differential in ASD**

One of the strongest risk factors for developing ASD is male sex. ASD prevalence in males is 3 to 4 fold higher than in females (154–156). In the absence of intellectual disability, this ratio increases further to 7:1 (157). Baron-Cohen et al. (158) has proposed the “extreme male brain” theory to explain the significant sex differential in ASD incidence. This theory suggests that excess prenatal androgen exposure contributes to the development of autistic traits in offspring by amplifying traits thought to be more typical of males, such as systemization, while diminishing traits commonly associated the femininity, such as empathy (158). Sex steroid hormones have long been thought to exert profound effects on the sexual dimorphism of the brain (159, 160); however, the exact mechanism has yet to be fully understood.

The “aromatization” hypothesis proposes that the roles of estradiol and testosterone in fetal neurodevelopment are intertwined (161), as masculinization of the rodent fetal brain is dependent upon the conversion of testosterone to estradiol by the enzyme aromatase (162, 163). In primates, reliance on this mechanism to explain masculinization of the human fetal brain remains unproven. Unlike primates, alpha-fetoprotein in rodents has a high binding affinity to circulating estradiol thereby sequestering estradiol and preventing it from entering and masculinizing the fetal rodent brain (164). Therefore, only the sex steroids produced by the fetal rodent influence brain masculinization. The assumption that estradiol’s masculinizing role in the rodent fetal brain could be extrapolated to the human fetal brain is significantly flawed because it fails to account for the substantial difference between these mammals in regards to *in utero* estradiol sequestration by alpha-fetoprotein.

Zhao et al. (165) describes a multiple threshold liability model to explain the sex difference in ASD risk. This model theorizes that females require a higher genetic mutation load relative to their male counterparts to develop ASD thus contributing to ASD’s male predominance. Werling and Geschwind (157) speculate that these mutations may interact with androgen-related mechanisms in families with affected females, as prior studies have found an association with ASD and genes that modulate sex-steroid function (166–168). As steroid hormone receptors exert epigenetic effects through DNA methylation and histone acetylation (169–172), it is possible that epigenetic modifications in response to *in utero* sex-steroid hormone exposure affect sex-specific neurodevelopmental processes.

**Sex-Specific Fetal and Placental Responses to Adversity**

Fetal growth, development, and HPA axis programming in the setting of obstetric adversity differ by fetal sex (173–175). These sex-specific responses serve as additional mechanisms in which to consider male ASD predominance (see Figure 2). As the placenta is derived from extra-embryonic tissues, the placenta has the same sex as the fetus (178). Evidence suggests that
FIGURE 2 | Sex-specific fetal and placental adaptations to maternal adversity. Placentas of male and female fetuses respond differently to mild forms of maternal adversity. In the placenta of female fetuses, multiple changes in glucocorticoid barrier enzyme activity, gene expression, and protein synthesis occur leading to decreased growth (176, 177). This is advantageous as it preserves fetal oxygen and nutrient delivery. In the placenta of male fetuses, minimal changes in gene and protein expression occur, and the male fetus continues to grow incurring increased vulnerability to adverse outcomes (176).

the placentas of male and female fetuses differ in response to adverse prenatal environments through modulation of steroid pathways, placental genes, and protein synthesis (176). Placental growth and structure differ by sex, with male placentas being smaller in size but more efficient at nutrient and oxygen delivery (179, 180). Fetal growth depends upon the limited capacity of the maternal-placental interface to deliver oxygen and nutrients. Thus, greater placental efficiency among males precipitates faster somatic growth while increasing vulnerability to in utero perturbations (179, 181). This may have deleterious neurodevelopmental consequences, as fetal brain development relies on the availability of oxygen and nutrients such as fatty acids, glucose, and amino acids (131, 182, 183). In contrast, female placentas may have superior ability to buffer and adapt to suboptimal prenatal conditions (180).

Newborns differ by sex in regards to birth weight, morbidity, and mortality. This is attributable at least in part to sex-specific adaptations that regulate the balance between fetal growth and extra-uterine survival (184, 185). In the setting of mild physical adversity (i.e., chronic maternal asthma), changes in placental 11β-HSD glucocorticoid barrier enzyme activity, gene expression, and protein synthesis occur and coincide with reduced female fetal growth (176, 177). This prepares the female fetus for future adverse events through preservation of oxygen and nutrient delivery. In pregnancies complicated by mild pre-eclampsia, male and female fetuses differ in growth progression mediated by differential fetal microvascular (186) and placental inflammatory cytokine responses (187). In the setting of maternal hyperglycemia, males demonstrate greater hyperglycemic growth stimulation (188) and higher incidences of respiratory distress (175). The sex hormones estradiol and testosterone stimulate opposing processes on fetal lung development: estradiol facilitates surfactant production while testosterone promotes lung tissue proliferation at the expense of lung maturation (189). Collectively, sex-specific responses to obstetrical adversity leave males less physiologically prepared for survival, particularly if birth were to occur prematurely (176).

A growing body of evidence demonstrates a link between placental pathology and ASD. Anderson et al. (43) found increased trophoblastic inclusions in the placentas of fetuses who later developed ASD. Trophoblastic inclusions, a histological finding that results from atypical growth and folding of the placenta (190), are more common in genetically atypical gestations (191–194). Furthermore, studies of high ASD risk cohorts (defined by having at least one older sibling with ASD) also found increased placental trophoblastic inclusions (195) in addition to altered placental morphology (196) and placental chorionic surface vascular networks (197). The specific morphological changes found, such as increased thickness and roundness, may reflect decreased ability to adapt to variations in the prenatal environment (196). Notably, variations within the placental chorionic surface vascular networks may be
the result of atypical vasculogenesis and angiogenesis (197). Several conditions associated with ASD, such as pre-eclampsia (198), intrauterine growth restriction (41), and pre-term birth (16) are also attributed to placental vascular abnormalities (199–201). In ASD individuals, Straughen et al. demonstrated an association between placental inflammation, maternal vascular malperfusion, and ASD (9) that occurred more prominently among males.

Sex-specific placental signaling and epigenetic phenomena in fetal adaption to nutrient availability and maternal stress are exemplified by the X-linked gene O-linked N-acetylgalacosamine transferase (OGT) (131, 202). OGT induces glucose-sensitive epigenetic changes that influence immune responses, steroidogenic activity, and fetal development. Because placental X inactivation spares OGT (20) such that the female placenta has two active gene copies while the male placenta has only one, OGT expression and interaction with steroid receptors demonstrate sex-specificity (203, 204). This provides an additional potential mechanism through which maternal metabolic conditions (i.e., hyperglycemia, insulin insensitivity) could influence the sex-differential observed in ASD (20).

STEROID-RELATED BIOMARKERS IN ASD

In utero steroidogenesis occurs through the well-coordinated interactions among the mother, placenta, and fetus (21, 22). The placenta is the main orchestrator of adaptions by the maternal-fetal-placental unit of steroidogenic activity in response to in utero and external environmental cues (205). As the transcriptome of the placenta changes throughout pregnancy (206), expression of placental genes involved in steroid hormone regulation consequentially shift (205). This section is a review of steroid-related biomarkers that have been associated with ASD accompanied by a brief summary of their potential connection to ASD.

Androgens

Multiple studies have demonstrated associations between ASD/ASD traits and amniotic fluid androgen levels (i.e., androstenedione and testosterone) (207–212) supporting the “extreme male brain” theory for ASD’s etiology proposed by Baron-Cohen et al. (158). Amniocentesis is typically performed between the 15th and 20th week of pregnancy, overlapping the critical gestational window when the male fetus produces peak amount of androgens to promote genital differentiation (213). This testosterone surge occurs between 11 and 17 weeks gestation (214).

Elevated androgen levels (androstenedione and testosterone) in amniotic fluid collected from pregnancies with male offspring correlated with later ASD diagnoses (212). Decreased eye contact (207), poorer quality of social relationships (211), increased restricted interests (211), reduced empathy (210), and higher autism trait scores (208, 209) have also been associated with elevated amniotic fluid androgen levels. Researchers conducting these amniotic fluid studies applied ASD trait severity measures that they developed, including the Quantitative Checklist for Autism in Toddlers (Q-CHAT) (215), the Childhood Autism Spectrum Test (CAST) (216), and the Child Autism Spectrum Quotient (AQ-Child) (217). In contrast, Kung et al. (218) found no relationship between autistic traits and amniotic testosterone levels in pregnancies resulting in typically developing children using the CAST. Elevated amniotic androgen levels associated with ASD found by Baron-Cohen et al. (212) also did not appear to persist in a re-analysis published in Baron-Cohen et al. (219).

Maternal serum has also been analyzed to investigate the relationship between prenatal androgen levels and the emergence of ASD (19). Maternal serum drawn during early 2nd trimester did not identify significant associations between maternal androgen levels and ASD among offspring (19). Although gestational timing for the maternal serum and amniotic fluid collections overlap, differences in study findings between Baron-Cohen et al. (212) and Bilder et al. (19) may result in part from differences in study purposes and designs. For the maternal serum study, investigators were particularly interested in measuring steroid-related biomarkers as potential intermediaries between ASD outcome and the effects of obstetrical conditions associated with steroid dysregulation (i.e., hypertension and diabetes) which they referred to as “prenatal metabolic syndrome” (PNMS). As such, both the ASD case and non-ASD control groups were enriched (by 50%) for the presence of PNMS exposure. Extrinsic testosterone exposure to the fetus is measurable in maternal serum, though fetal testosterone production cannot be measured in maternal serum because androgen movement across the placenta is generally considered unidirectional from mother to fetus (220, 221). Testosterone levels in amniotic fluid, however, reflect both fetal testosterone exposure and production as the amniotic fluid collected is composed primarily of fetal urine.

In Park et al. (222), no association was found between androgen levels (testosterone, androstenedione, and DHEA) in umbilical cord blood and autistic traits at 12 and 36 months of age among the Early Autism Risk Longitudinal Investigation (EARLI) cohort using the Autism Observation Scale for Infants (AOSI) and Social Responsiveness Scale (SRS), respectively. The EARLI cohort were younger siblings of children with ASD. Several other studies have also failed to demonstrate an overall relationship between umbilical cord testosterone levels and ASD traits (223–225). Unlike the amniotic fluid and maternal serum studies described above, umbilical cord blood samples represent prenatal testosterone exposure at the time of parturition, far after the fetal testosterone surge occurs (214). Upon subdividing the sibling cohort into multiple groups based on proband and participant sex, umbilical cord blood testosterone levels correlated with ASD traits among siblings of female probands. The authors attributed their findings to the multiple threshold liability model (157, 165) suggesting a higher genetic load required for females to develop ASD.

Meconium androgen levels were also measured in the EARLI cohort (226). Findings demonstrated a positive correlation with some androgen levels (i.e., unconjugated testosterone and total DHEA) and SRS scores overall. Following stratification of the cohort by participant and proband sex, various associations were found between androgen levels and ASD traits at 12 and 36
months of age. Meconium begins accumulating in the 13th week of gestation, with the highest volume produced between 28 and 34 weeks gestation (227). As meconium represents cumulative exposures throughout gestation (228), it is difficult to link meconium steroid concentrations to a specific gestational time period of exposure.

Fetal testosterone in males is predominantly produced by the Leydig cells of the testes beginning around 8 weeks gestation (229). Placental human chorionic gonadotropin (hCG), in tandem with luteinizing hormone (LH) produced in the fetal pituitary gland, stimulates testosterone synthesis by the testes during early gestation (214, 230–233). Interestingly, LH and hCG share a common receptor transcribed from a single gene (234). Placental hCG production rapidly increases following implantation until it reaches its apex at the end of the first trimester (235). Following this, hCG levels progressively reach a nadir by 18–20 weeks gestation (236–238). As hCG levels decline, LH levels rise. From 8 to 24 weeks of gestation, the testosterone level in males substantially exceeds that of females (239), which is believed to impart neurodevelopmental effects resulting in sex-specific behavioral differences (240). However, the timing and mechanism in which this occurs in the human fetal brain has not been definitively determined. While the fetal adrenal gland can also synthesize testosterone, the amount is negligible (241, 242) and its contribution to amniotic fluid androgen levels is not clearly established.

hCG
Aside from stimulating testosterone synthesis, hCG serves a variety of functions, including pregnancy maintenance through stimulation of the corpus luteum to secrete progesterone (129, 243). Additionally, hCG has been associated with angiogenesis, mediation of immune tolerance, umbilical cord development, myometrial contraction suppression, and fetal organ growth and differentiation (244–246). To our knowledge, only one study has directly examined 2nd trimester maternal serum hCG levels in relation to ASD risk. Windham et al. (247) found a U-shaped relationship (i.e., both higher and lower levels) between hCG levels associated with increased ASD risk among offspring, particularly in males.

Elevated hCG levels during the 2nd trimester have also been linked to complications such as preeclampsia (248–250), intrauterine growth restriction (IUGR) (248), pre-term delivery (248, 250, 251), low birth weight (250), and fetal death (250, 251). As the placenta secretes hCG in response to stress hormones (252), an adverse prenatal environment may contribute to steroid dysregulation in ASD through elevated hCG exerting its influence on testosterone synthesis in male fetuses. This proposed mechanism of aberrations within the fetal steroid hormonal milieu aligns with findings of elevated 2nd trimester amniotic fluid testosterone levels associated with ASD described above. Interestingly, hCG can also stimulate fetal adrenal DHEA(S) secretion during the 2nd trimester (253). As DHEA(S) is a substrate for placental estradiol synthesis, abnormalities in 2nd trimester estradiol and testosterone linked to ASD development may share a common genesis involving the placental response to adversity.

Estrogens and Progesterone
While prior investigations have focused on androgens, recent research studies have explored the potential role that estrogen and progesterone may play in the development of ASD. Bilder et al. (19) found significantly higher estradiol levels in early 2nd trimester maternal serum associated with ASD among offspring. As described above, both ASD and comparison cohorts were enriched for PNMS exposure. Along with higher estradiol levels, lower SHBG levels were also identified, suggesting the potentiation of estradiol activity in pregnancies associated with ASD as SHBG binds biologically active estrogens rendering them inert (254). Estradiol, rather than estriol, was selected as the estrogen of interest for this study because maternal estradiol levels represent placental estrogen activity more accurately through estradiol's substantially higher potency (255), longer estrogen receptor binding duration (256), and higher maternal serum concentrations (257, 258). Because maternal serum estradiol levels result from, and reflect, placental estradiol production by this gestation window (130), Bilder et al. (19) interpreted these results as indicating increased ASD risk associated with elevated placental estradiol production and activity. Higher placental estradiol production could result from greater fetal steroidogenic activity, and increased placental estradiol activity could facilitate premature fetal HPA axis maturation in the early 2nd trimester. Bilder et al. (19) did not find a significant association between serum progesterone concentrations and ASD risk.

Baron-Cohen et al. (219) also identified higher estrogen levels (i.e., estradiol, estril, and estrone), along with increased progesterone levels, in 2nd trimester amniotic fluid of male offspring with ASD relative to controls. Notably, elevated estradiol was the most significant predictor of subsequent ASD development. Baron-Cohen et al. (219) attributes the link between higher amniotic estrogens, progesterone, and ASD among offspring to increased fetal steroidogenic activity in ASD's etiologic pathway.

Elevated ASD risk associated with higher prenatal estrogen levels in maternal serum (19) and amniotic fluid (219) contrast with prior study results from Windham et al. (247), which demonstrated lower unconjugated estriol levels in 2nd trimester maternal serum. Estriol is a weak estrogen produced exclusively during pregnancy and requires fetal liver enzyme activity in its synthesis pathway (257, 258). Estriol levels in Windham et al. (247) were initially measured as a component of a prenatal integrated screening test for aneuploidy and neural tube defects. Low maternal serum estriol levels have been used for decades as a clinical indicator for obstetric complications (259), such as placental insufficiency (260), fetal growth restriction (261), pre-eclampsia (262), preterm birth (247), low birth weight (263), and pregnancy loss (260). Windham et al. (247) attributes study findings to the involvement of hormones in the development of ASD through their influence on fetal development and signaling activity in the CNS and immune system.

Cortisol
Baron-Cohen et al. (212) identified elevated cortisol levels in the amniotic fluid collected during the pregnancies of male
offspring who developed ASD, though this finding was not replicated in Baron-Cohen et al. (219). However, Baron-Cohen and colleagues (212, 219) conclude that the findings from both studies support the presence of increased fetal steroidogenic activity in ASD. The significant diurnal variation in serum cortisol concentrations preempts its use as a biomarker in banked maternal serum samples from most large obstetric studies because standardization of serum collection times for these studies is typically not implemented.

**Sex Hormone-Binding Globulin (SHBG)**

Bilder et al. (19) found an inverse relationship between maternal serum SHBG levels and risk for diabetes/hypertension exposure and ASD. The highest SHBG levels were measured for the cohort with neither PNMS exposure nor ASD. Conversely, the lowest SHBG levels occurred in the cohort with both PNMS exposure and ASD. In addition to binding estrogens and testosterone, SHBG also serves as a serum biomarker for insulin sensitivity that supersedes its relationship with sex hormones regardless of sex, age, and pregnancy status (264). Even among pregnancies without clinical PNMS manifestations, SHBG levels were lower in the ASD cohort compared to either non-ASD cohorts, suggesting the presence of exposure to a subclinical metabolic condition during gestation in these offspring who developed ASD. Unlike most serum biomarkers for insulin sensitivity, SHBG measures require no specific collection time (e.g., time of day or proximity to caloric consumption) to ensure meaningful results interpretation. SHBG has been studied as a predictive 1st and early 2nd trimester biomarker for the emergence of gestational diabetes (265–267). Thus, SHBG is a useful biomarker for investigating maternal insulin sensitivity as a prenatal risk factor within maternal serum samples banked for non-specific purposes.

**“Estimated Fetal DHEA”**

As a post hoc analysis, Bilder et al. (19) calculated a value from maternal serum measurements of estradiol, DHEA, and DHEAS to estimate the relative contribution by the fetal adrenal gland to the DHEA substrate supply for placental estradiol production (EF-DHEA). The area under the curve for EF-DHEA used to predict ASD among offspring exceeded those of its measured components. This was interpreted to indicate that the relationship between elevated maternal serum estradiol and increased ASD risk may in part be driven by excess fetal adrenal activity in early 2nd trimester. The EF-DHEA calculation was created specifically for this study and has not been validated in animal models nor have these findings been replicated. However, EF-DHEA findings are consistent with the amniotic fluid results, particularly elevated cortisol, from Baron-Cohen et al. (212) demonstrating an association between ASD among offspring and increased fetal steroidogenic activity during this gestational window.

**Synthesis of Pertinent Biomarker Findings**

Figure 3 links heightened in utero stress from inflammation, stressors, and metabolic disturbances to perturbation within the prenatal hormone milieu. Through pCRH stimulation, the placenta upregulates fetal HPA axis activity in response to in utero stress. Subsequently, the fetal adrenal glands increase DHEA(S) synthesis leading to elevated placental estradiol production. Higher placental estradiol and pCRH production promotes HPA axis maturation denoted by fetal adrenal de novo cortisol synthesis. In response to in utero stress, the placental also increases hCG production which stimulates fetal gonadal testosterone synthesis.

**DISCUSSION**

This review provides an up-to-date synopsis of the current evidence and supported theories regarding the role that the in utero steroid environment may play in ASD pathophysiology. Considering placental steroid hormone biosynthesis, metabolism, and transport (205), prenatal steroid dysregulation may be attributed to disruptions in vital components of placental structure and function in response to an adverse maternofetoplacental environment. In particular, stress, inflammation, and metabolic abnormalities can contribute to morphological and functional placental changes that affect nutrient and oxygen exchange, the protective transplacental barrier, and hormone synthesis (268, 269).

Obstetric conditions associated with ASD that may contribute to an adverse prenatal environment include hypertensive disorders of pregnancy (i.e., chronic, gestational, de novo or superimposed preeclampsia) (13, 14, 35–37), maternal immune dysfunction (5, 7–9), pre-existing/gestational diabetes (3, 10), pre-pregnancy obesity (11), gestational weight gain (12), and PCOS (4, 15). Notably, common indicators or complications of placental insufficiency also overlap with ASD risk factors, including small for gestational age (in utero) growth restriction, prematurity, maternal infection, and maternal metabolic syndrome (16, 38–42). As the placenta is critical for fetal growth and development, adverse prenatal environments that impact the placenta may increase fetal stress and influence fetal programming, thereby contributing to ASD etiology.

The placenta shares the sex of the fetus as it is derived from extra-embryonic tissues (178). Numerous studies have documented that placentas of male and female fetuses differ in response to adverse prenatal environments (270–273). Specifically, placental signaling and gene expression influence sex-specific differences in fetal adaption to the in utero environment related to nutrient availability, maternal stress, and immune response (131, 202). In the setting of mild adversity, ongoing somatic growth of male fetuses confers increased vulnerability to subsequent adverse events (176, 177) that can influence neurodevelopment. Additionally, evidence of placental pathology appears more prominent from pregnancies of male offspring with ASD compared to those of their female counterparts. Further investigation of placental pathology in ASD is needed, particularly as it relates to fetal/placental sex differences.

Second trimester serves as a critical time for fetal steroidogenic activity in regards to fetal HPA axis maturation. Multiple ASD epidemiologic studies highlight the 2nd trimester as the period
of greatest fetal vulnerability to stressful maternal life events (5, 6, 63). Bilder et al. (19) and Baron-Cohen et al. (212, 219) interpret the link between higher estrogen levels and ASD risk as an indicator of elevated fetal steroidogenic activity in the 2nd trimester of offspring who develop ASD. While Baron-Cohen et al. (212, 219) conceptualize fetal steroidogenic activity more broadly, particularly in regards to fetal androgen production, Bilder et al. (19) focuses on excess fetal adrenal activity and premature fetal HPA axis maturation. By strengthening the maternal-fetal cortisol gradient, placental estradiol reduces the amount of maternal cortisol in the fetal compartment (139) thereby easing maternal cortisol suppression of the fetal HPA axis and promoting its maturation. Fetal steroidogenic activity is enhanced by CRH released by the fetal hypothalamus and placenta (124, 145, 274–276). CRH production is stimulated by stress, inflammation, and hypoxia providing a mechanism through which obstetrical adversity could contribute to increased fetal steroidogenic activity and early HPA axis maturation (115, 150, 277).

The relationship between higher 2nd trimester estrogen levels and increased ASD risk is intriguing as estrogen is widely seen as an indicator of maternal and fetal health. Estradiol acts to preserve fetal viability during in utero stress through suppression of inflammation (278, 279) and uterine artery dilation that increases oxygen and nutrient supply to the fetus (280, 281). Estradiol also mediates several critical factors in neurodevelopment providing an overall neuroprotective benefit (162). From the perspective of fetal viability, excess estradiol in the early 2nd trimester can stimulate precocious fetal HPA axis maturation in preparation for extrauterine life. As described above, low—rather than high—maternal serum estrogen levels predict several conditions related to maternal and fetal adversity. Therefore, it is possible that elevated estradiol in early 2nd trimester maternal serum and amniotic fluid may be the result of a compensatory rather than primarily pathologic mechanism. However, it must be noted that the historical obstetric practice of using a synthetic estrogen to foster healthy pregnancies was quite misguided. The use of the synthetic estrogen diethylstilbestrol (DES) in pregnant women during the mid-1900’s was halted when exposed adolescent and young adult female offspring were found to develop a rare type of cancer, vaginal adenocarcinoma (282). Subsequent studies have found transgenerational adverse effects of DES exposure, as reproductive tract and immunologic abnormalities have occurred in exposed male and female offspring (283). Grandchildren of exposed women were also found to have a higher incidence of ADHD (284). To our knowledge, there have been no studies published that report on an epidemiologic investigation of ASD risk associated with DES exposure. Although DES exposure differs in many respects from increased placental estrogen synthesis, such a study could improve understanding of estrogen’s potential role in ASD’s etiology.

An early theory connecting the prenatal steroid environment with ASD conceptualizes ASD as an extreme manifestation of male cognitive traits and implicates excess in utero androgen exposure in ASD’s etiology (158). Although elevated amniotic testosterone levels were associated with the presence of ASD traits in most (207–211), but not all studies (218), results regarding ASD diagnosis and testosterone concentrations have been more variable (212, 219). Two amniotic fluid studies and a maternal
serum study found no relationship between testosterone and ASD (19, 218, 219). Results from umbilical cord blood and meconium analyses were mixed (222, 226). Disparate findings on androgen biomarkers may be attributable to differences in sample type, gestational timing, ASD outcome measures, and cohort characteristics. Additional investigations are needed which implement multiple sampling strategies and gestational time points in a large obstetrical cohort to clarify the relationship between androgen levels throughout pregnancy and ASD risk.

Overall, prior research findings have established that an altered prenatal environment is a component of ASD pathogenesis. However, the exact process detailing the interaction between diverse prenatal factors and increased ASD risk remains unclear. While several studies link various aspects of perturbations in utero to ASD development, to our knowledge, there has been a lack of a unifying paradigm. Based on our current understanding, we propose that disruption within the maternofetoplacental unit initiates a causal sequence resulting in placental changes, thereby influencing fetal programming, steroid hormone modulation, and HPA axis development in ASD.

Factors that contribute to disruption within the maternofetoplacental unit include metabolic disturbances, inflammatory conditions, and stressors. These broad categories are manifested by several obstetric conditions that are associated with ASD development. The placenta reacts to changes in utero through adaptations that differ based on sex, which are disadvantageous to male fetuses. Fetal programming is affected, which may have neurodevelopmental implications. Considering the placenta’s endocrine functions, steroid hormone modulation is also impacted which could alter HPA axis development and functioning. This may be relevant to HPA axis dysregulation found in some individuals with ASD.

Current literature findings support multidisciplinary research efforts to investigate the manner in which the in utero steroid milieu and fetal steroidogenic activity interact with genetic/epigenetic, environmental, inflammatory, and obstetrical ASD risk factors. Studies examining these interaction effects on fetal neuroendocrine development may identify feasible intervention targets that could reduce risk for neonatal morbidity/mortality and childhood neurodevelopmental disabilities. In particular, elucidating the link between the in utero steroid environment and immune response may provide an opportunity to optimize both immediate outcomes and long-term neurodevelopmental functioning.

**AUTHOR CONTRIBUTIONS**

WW conceptualized and designed all components of the paper, drafted the initial manuscript, reviewed, and revised the manuscript. SD conceptualized the obstetrical components of the paper, reviewed, and revised the manuscript. DB supported the conceptualization of all components of the paper, reviewed and revised the manuscript. All authors approve the final manuscript as submitted and agree to be accountable for all aspects of the work.

**FUNDING**

This scientific review was supported by the University of Utah Neuroscience Initiative.

**ACKNOWLEDGMENTS**

We would like to thank Dr. Michael Varner, MD, for providing an expert critique of this manuscript.

**REFERENCES**

1. Association AP. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. Arlington, VA American Psychiatric Association (2013).
2. Khouri R, Alizadeh M. Maternal excessive gestational weight gain as a risk factor for autism spectrum disorder in offspring: a systematic review. *BMC Pregnancy Childbirth.* (2020) 20:645. doi: 10.1186/s12884-020-03324-w
3. Gardener H, Spiegelman D, Buka SL. Perinatal and neonatal risk factors for autism: a Comprehensive meta-analysis. *Pediatrics.* (2011) 128:444–55. doi: 10.1542/peds.2010-1036
4. Hisle-Gorman E, Susi A, Stokes T, Gorman G, Erdie-Lalena C, Nylund CM. Prenatal, perinatal, and neonatal risk factors of autism spectrum disorder. *Pediatric Res.* (2018) 84:190–8. doi: 10.1038/pr.2018.23
5. Beversdorff DQ, Stevens HE, Margolis KG, Van De Water J. Prenatal stress and maternal immune dysregulation in autism spectrum disorders: potential points for intervention. *Curr Pharm Design.* (2020) 25:4331–43. doi: 10.2174/138161282566619119093335
6. Kinney DK, Miller AM, Crowley DJ, Huang E, Gerber E. Autism prevalence following prenatal exposure to hurricanes and tropical storms in Louisiana. *J Autism Dev Disord.* (2008) 38:481–8. doi: 10.1007/s10803-007-0414-0
7. Madore C, Leyrolle Q, Lacabanne C, Bemmarar-Badel A, Joffre C, Nadjar A, et al. Neuroinflammation in autism: plausible role of maternal inflammation, dietary omega 3, and microbiota. *Neural Plasticity.* (2016) 2016:1–15. doi: 10.1155/2016/3597209
8. Patterson PH. Maternal infection and immune involvement in autism. *Trends Mol Med.* (2011) 17:389–94. doi: 10.1016/j.molmed.2011.03.001
9. Straughen JK, Misra DP, Divine G, Shah R, Perez G, Vanhorn S, et al. The association between placental histopathology and autism spectrum disorder. *Placenta.* (2017) 57:183–8. doi: 10.1016/j.placenta.2017.07.006
10. Xu G, Jing J, Bowers K, Liu B, Rao W. Maternal diabetes and the risk of autism spectrum disorders in the offspring: a systematic review and meta-analysis. *J Autism Dev Disord.* (2014) 44:766–75. doi: 10.1007/s10803-013-1928-2
11. Sanchez CE, Barry C, Sahlhok A, Russell K, Majors A, Kollins SH, et al. Maternal pre-pregnancy obesity and child neurodevelopmental outcomes: a meta-analysis. *Obesity Rev.* (2018) 19:464–84. doi: 10.1111/obr.12643
12. Bildner DA, Bakian AV, Viskochil J, Clark EAS, Botts EL, Smith KR, et al. Maternal prenatal weight gain and autism spectrum disorders. *Pediatrics.* (2013) 132:e1276–e83. doi: 10.1542/peds.2013-1188
13. Dachew BA, Mamun A, Maravilla JC, Alati R. Pre-eclampsia and the risk of autism-spectrum disorder in offspring: meta-analysis. *Br J Psychiatry.* (2018) 212:142–7. doi: 10.1192/bjp.1
14. Maher GM, McCarthy FP, McCarthy CM, Kenny LC, Kearney PM, Khashan AS, et al. A perspective on pre-eclampsia and neurodevelopmental outcomes in the offspring: does maternal inflammation play a role? *Int J Dev Neurosci.* (2019) 77:89–76. doi: 10.1016/j.ijdevneu.2018.10.004
15. Kosidou K, Dalman C, Widman L, Arver S, Lee BK, Magnusson C, et al. Maternal polycystic ovary syndrome and the risk of autism spectrum
disorders in the offspring: a population-based nationwide study in Sweden. Mol Psychiatry. (2016) 21:1441–8. doi: 10.1038/mp.2015.183

16. Agrawal S, Rao SC, Bulsara MK, Patole SK. Prevalence of autism spectrum disorder in preterm infants: a Meta-analysis. Pediatrics. (2018) 142:e20180134. doi: 10.1542/peds.2018-0134

17. Bolte S, Girdler S, Marschik PB. The contribution of environmental exposure to the etiology of autism spectrum disorder. Cell Mol Life Sci. (2019) 76:1275–97. doi: 10.1007/s00018-019-2988-4

18. Modabbernia A, Velthorst E, Reichenberg A. Environmental risk factors for autism: an evidence-based review of systematic reviews and meta-analyses. Mol Autism. (2017) 8:13. doi: 10.1186/s13229-017-0121-4

19. Bilder DA, Esplin MS, Coon H, Burghardt P, Clark EAS, Fraser A, et al. Early second trimester maternal serum steroid-Related biomarkers associated with autism spectrum disorder. J Autism Dev Disord. (2019) 49:4572–83. doi: 10.1007/s10803-019-04162-2

20. Bale TL. The placenta and neurodevelopment: sex differences in prenatal vulnerability. Dialogues Clin Neurosci. (2016) 18:459–64. doi: 10.31887/DCNS.2016.18.4/tbale

21. Kallen CB. Steroid hormone synthesis in pregnancy. Obstet Gynecol Clin North Am. (2004) 31:795–816, x. doi: 10.1016/j.ogc.2004.08.009

22. Murphy VE, Smith R, Giles WB, Clifton VL. Endocrine regulation of human fetal growth: the role of the mother, placenta, and fetus. Endocr Rev. (2006) 27:141–69. doi: 10.1210/er.2005-0011

23. Straub RH. The complex role of estrogen in endometrium. Endocr Rev. (2007) 28:521–74. doi: 10.1210/er.2007-0001

24. Marzi M, Vigano A, Trabattoni D, Villa ML, Salvaggio A, Clerici E, et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol. (1996) 106:127–33. doi: 10.1046/j.1365-2249.1996.d01-809.x

25. Matalka KZ. The effect of estradiol, but not progesterone, on the production of cytokines in stimulated whole blood, is concentration-dependent. Neuro Endocrinol Lett. (2004) 24:185–91.

26. Sabahi F, Rola-Pleszcynski M, O’Connell S, Frenkel LD. Qualitative and quantitative analysis of t lymphocytes during normal human pregnancy. Am J Reprod Immunol. (1995) 33:381–93. doi: 10.1111/j.1600-0897.1995.tb00907.x

27. Rowe JH, Ertelt JM, Xin L, Way SS. Regulatory t cells and the immune response during pregnancy are associated with an inflammatory state: evidence from hematological findings and cytokine levels. BMC Med Child. (2019) 19:237. doi: 10.1186/s12884-019-2383-7

28. Ziolo KB, Lehtonen L, Tran PL, Suominen A, Lehti V, Banerjee D, et al. Exposure to hypertensive disorders of pregnancy increases the endometrial decidualization: the primary driver of pregnancy health. Am J Reprod Immunol. (2019) 82:656–63. doi: 10.1111/ajr.131671

29. Nukada T, Ono T, Hayakawa M, Ogasawara Y, Kita S. Preeclampsia, placental insufficiency, and autism spectrum disorders in the offspring: a population-based nationwide study in Sweden. BMJ Open. (2019) 9:206314.e1–e9. doi: 10.1136/bmjopen-2012.01044

30. Barek K, Walker CK, Bremer AA, Baker AS, Ozonoff S, Hansen RL, et al. Maternal metabolic conditions and risk for autism and other neurodevelopmental disorders. Pediatrics. (2012) 129:e1121–e8. doi: 10.1542/peds.2011-2583

31. Lampi KM, Lehtonen L, Tran PL, Suominen A, Lehti V, Banerjee D, et al. Exposure to hypertensive disorders of pregnancy increases the endometrial decidualization: the primary driver of pregnancy health. Am J Reprod Immunol. (2019) 82:656–63. doi: 10.1111/ajr.131671

32. Zerbo O, Qian Y, Yoshiha C, Grether JK, Van De Water J, Croen LA. Maternal infection during pregnancy and autism spectrum disorders. J Autism Dev Disord. (2015) 43:4018–25. doi: 10.1007/s10803-013-1963-3

33. Anderson GM, Jacobs-Nannard A, Chawarska K, Volkmar FR, Kliman HJ. Placental trophoblast inclusions in autism spectrum disorder. Biol Psychiatry. (2007) 61:487–91. doi: 10.1016/j.biopsych.2006.03.068

34. Miura S, Li Y, Umezawa H, Lazzaro L, Massawe SN. Hypertensive disorders of pregnancy are associated with an inflammatory state: evidence from hematological findings and cytokine levels. BMC Pregnancy Childbirth. (2019) 19:237. doi: 10.1186/s12884-019-2383-7

35. Nasso T, Mafioletti J, Lopez-Tello J, Sferruzzi-Perri AN. The role of placental hormones in mediating maternal adaptations to support pregnancy and lactation. Front Physiol. (2018) 9:1091. doi: 10.3389/fphys.2018.01091

36. Li M, Fullin MD, Riley A, Landa R, Walker SO, Silverstein M, et al. The association of maternal obesity and diabetes with autism and other developmental disabilities. Pediatrics. (2016) 137:e20152206–e2015. doi: 10.1542/peds.2015-2206

37. Xiang AH, Wang X, Martinez MP, Page K, Buchanan TA, Feldman RK. Maternal type 1 diabetes and risk of autism in offspring. JAMA. (2018) 320:809. doi: 10.1001/jama.2018.7614

38. Vambergue A, Fajardy I. Consequences of gestational and pregestational diabetes on placentation and birth weight. World J Diabetes. (2011) 2:196–203. doi: 10.4239/wjd.v2.i11.196

39. Vignoles P, Gire C, Mancini J, Bretelle F, Boubli L, Janky E, et al. Gestational diabetes mellitus: definition, aetiological and clinical aspects. Eur J Endocrinol. (2016) 174:R43–51. doi: 10.1530/EJE-15-0378

40. Fogden AL, Li J, Forhead AJ. Glucocorticoids and the preparation for life after birth: are there long-term consequences of the life insurance? Proc Nutr Soc. (1998) 57:113–22. doi: 10.1079/PNS199800017

41. Gewolb IH. Effect of high glucose on fetal lung maturation at different times in gestation. Am J Obstetr Gynecol. (2005) 192:196–203. doi: 10.1016/j.ajog.2002.08.059

42. Piccione I. Preeclampsia, placental insufficiency, and autism spectrum disorders in the offspring: a population-based nationwide study in Sweden. Arch Gynecol Obstet. (2019) 299:136–49. doi: 10.1007/s00404-019-10391-1

43. Desoye G, Hauguel-De Mouzon S. The human placenta in gestational diabetes mellitus: the insulin and cytokine network. Diabetes Care. (2007) 30(Suppl. 2):S12–6. doi: 10.2337/dc07-S203

44. Windham GC, Anderson M, Lyall K, Daniels JL, Kral TVE, Croen LA, et al. Maternal pre-pregnancy body mass index and gestational weight gain in relation to autism spectrum disorder and other developmental disorders in offspring. Autism Res. (2019) 12:316–27. doi: 10.1002/aur.2057
Worsham et al. Prenatal Hormone Milieu in ASD

68. Mandy M, Nyirenda M. Developmental origins of health and disease: 
Barker DJP. The origins of the developmental origins theory. 
57. Kelly AC, Powell TL, Jansson T. Placental function in maternal obesity. 
58. Lof M, Hilakivi-Clarke L, Sandin S S, De Assis S, Yu W, Weiderpass D. Dietary fat intake and gestational weight gain in relation to estradiol and progesterone plasma levels during pregnancy: a longitudinal study in swedish women. 
BMJ. 
72. Kelstrup L, Damm P, Mathiesen ER, Hansen T, Vaag AA, Pedersen 
73:234–41. doi: 10.1097/PSY.0b013e318206a2ce 
63. Class QA, Lichtenstein P, Långström N, D’Onofrio BM. Timing of prenatal in utero 
62. Kallak TK, Hellgren C, Skalkidou A, Sandelin-Francke L, Ubhayasekhera K, 
61. Kallak TK, Hellgren C, Skalkidou A, Sandelin-Francke L, Ubhayasekhera K, Bergquist J, et al. Maternal and female fetal testosterone levels are associated with maternal age and gestational weight gain. 
7op J Endocr. (2017) 177:379–88. doi: 10.1530/EJE-17-0207 
64. Drake AJ, Reger M, Dziboev I, Sweat V, Tirsi A, Javier E, et al. Hypothalamic-Pituitary-Adrenal axis dysregulation and memory impairments in type 2 diabetes. 
7op J Endocrinol Metab. & Metabolism. (2007) 92:243–49. doi: 10.1210/jc.2006-2540 
69. Koster A, Butler S, Butland K, Chalmers J, Erens B, et al. Fetal programming of adult disease: implications for programming and future health. 
Int Health. (2011) 3:231–40. doi: 10.1002/ioh.428 
33. Silverman BL, Metzger BE, Cho NH, Loeb CA. Impaired glucose tolerance in adolescent offspring of diabetic mothers. 
Diabetes Care. (2007) 30 (Suppl. 2):S169–74. doi: 10.2337/dc06-S169 
71. Kelstrup L, Damm P, Mathiesen ER, Hansen T, Vaag AA, Pedersen O, et al. Insulin resistance and impaired pancreatic β-cell function in adult offspring of women with diabetes in pregnancy. 
J Clin Endocrinol Metab. (2013) 98:3793–801. doi: 10.1210/jc.2013-1536 
47. Silverman BL, Metzger BE, Cho NH, Loeb CA. Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal hyperinsulinism. 
Diabetes Care. (1995) 18:611–7. doi: 10.2337/diacare.18.5.611 
70. Freeman DJ. Effects of maternal obesity on fetal growth and body composition: implications for programming and future health. 
Semin Fetal Neonatal Med. (2015) 11:133–8. doi: 10.1016/j.siny.2015.09.001 
77. Parker DJP. Sir richard doll lecture. Developmental origins of chronic disease. 
Public Health. (2012) 126:185–9. doi: 10.1016/j.puhe.2011.11.014 
78. Lau C, Rogers JM, Desai M, Ross MG. Fetal programming of adult disease: implications for prenatal care. 
Obstet Gynecol. (2011) 117:978–85. doi: 10.1097/FIGO.0b013e318212110f 
79. Neri C, Edlow AG. Effects of maternal obesity on fetal programming: molecular approaches. 
Cold Spring Harbor Perspect Med. (2015) 6:a026591–a. doi: 10.1101/cshperspect.a026591 
80. West NA, Crume TL, Maligie MA, Dabelea D. Cardiovascular risk factors in children exposed to maternal diabetes in utero. 
Diabetologia. (2011) 54:504–7. doi: 10.1007/s00125-010-2008-1 
81. Tam WH, Ma RCW, Ozaki R, Li AM, Chan MMH,uyen LY, et al. In utero exposure to maternal hyperglycemia increases childhood cardiometabolic risk in offspring. 
Diabetes Care. (2017) 40:679–86. doi: 10.2337/dc16-2397 
82. Dabelea D, Hanson RL, Lindsey RS, Pettitt DJ, Imperatore G, Gabor MM, et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity; a study of discordant siblings. 
Diabetes. (2000) 49:2208–11. doi: 10.2337/diabetes.49.12.2208 
83. Yogev Y, Visser GH. Obesity, gestational diabetes and pregnancy outcome. 
Semin Fetal Neonatal Med. (2009) 14:77–84. doi: 10.1016/j.siny.2008.09.002 
84. Orony A. Prenatal origin of obesity and their complications: gestational diabetes, maternal overweight and the paradoxical effects of fetal growth restriction and macrosomia. 
Reprod Toxic. (2011) 32:205–12. doi: 10.1016/j.reprotox.2011.05.002 
85. Stroik S, Hendrickson EA. Telomere replication—When the going gets tough. 
DNA Repair. (2010) 94:102875. doi: 10.1016/j.dnarep.2010.10.2875 
86. Ryzman K, Smith C. Epigenetic and developmental influences on the risk of obesity, diabetes, and metabolic syndrome. 
Diab Met Syndr Obesity Targets Therapy. (2015) 2015:295. doi: 10.2147/DMSO.S61296 
87. Xu J, Ye J, Wu Y, Zhang H, Luo Q, Han C, et al. Reduced fetal telomere length in gestational diabetes. 
PLoS ONE. (2014) 9:e86161. doi: 10.1371/journal.pone.0086161 
88. He J, Zhang A, Fang M, Fang R, Ge J, Jiang Y, et al. Methylation levels at iGF2 and gNAS dMRs in infants born to preeclamptic pregnancies. 
BMC Genomics. (2013) 14:472. doi: 10.1186/1471-2164-14-472 
89. Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, et al. Tumors, iGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. 
Endocr Rev. (2013) 34:798–826. doi: 10.1210/er.2012-1033 
90. Braun T, Challis JR, Newnham JP, Sloboda DM. Early-life glucocorticoid exposure: the hypothalamic-pituitary-adrenal axis, placental function, and long-term disease risk. 
Endocr Rev. (2013) 34:885–916. doi: 10.1210/er.2013-1012 
91. Moisio VG, Matthews SG. Glucocorticoids and fetal programming part 1: outcomes. 
Nat Rev Endocrinol. (2014) 10:391–402. doi: 10.1038/nrendo.2014.73 
92. Taylor JL, Corbett BA. A review of rhythm and responsiveness of cortisol in individuals with autism spectrum disorders. 
Psychoneuroendocrinology. (2011) 36:205–12. doi: 10.1016/j.psyneuen.2010.12.015 
93. Fulford AJ, Harbuz MS. Chapter 1.3 - an introduction to the hPA axis. In: Steckler T, Kalin NH, Reul JMHM, editors. Techniques in Endocrinology. 15: Elsevier (2005). p. 43–65. doi: 10.1016/S0921-0709(05)80066-9 
94. Herman J. Stress response: neural and feedback regulation of the hPA axis. Stress Sci Neuroendocr. (2010) 75:505–10. doi: 10.1080/0960052100360147 
95. Bruehl H, Rieger M, Dziboev I, Sweat V, Tirsi A, Javier E, et al. Hypothalamic-Pituitary-Adrenal axis dysregulation and memory impairments in type 2 diabetes. 
The Journal of Clinical Endocrinology & Metabolism. (2007) 92:2439–45. doi: 10.1210/jc.2006-2540 
96. Chang L, Sundaresh S, Elliott J, Anton PA, Baldi P, Licudine A, et al. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. 
Neurogastroent Motility. (2009) 21:149–59. doi: 10.1111/j.1365-2982.2008.01711.x 
97. Lopez-Duran NL, Kovacs M, George CJ. Hypothalamic–pituitary–adrenal axis dysregulation in depressed children and adolescents: a meta-analysis. 
Psychoneuroendocrinology. (2009) 34:1272–83. doi: 10.1016/j.psyneuen.2009.03.016
137. Salge AKM, Rocha KMN, Xavier RM, Ramalho WS, Rocha EL, Guimarães JV, et al. Macroscopic placental changes associated with fetal and maternal events in diabetes mellitus. Clinics (São Paulo). (2012) 67:1203–8. doi: 10.6061/clinics/2012/10/13

138. Wallace JG, Bellissimo CJ, Ely E, Fei Xia Y, Petrik JJ, Surette MG, et al. Obesity during pregnancy results in maternal intestinal inflammation, placental hypoxia, and alters fetal glucose metabolism at mid-gestation. Scient Rep. (2019) 9:17621. doi: 10.1038/s41598-019-54098-x

139. Pepe GJ, Burch MG, Albrecht ED. Estrogen regulates 11β-Hydroxysteroid dehydrogenase-1 and -2 localization in placental syncytiotrophoblast in the second half of primate pregnancy. Endocrinology. (2001) 142:4496–503. doi: 10.1210/endo.142.10.8434

140. Bölté E, Gattereau D, Joly M, Lefebvre Y. PERFORATION OF HUMAN term placenta IN siTu wItH c-19 anD c-18 STEROIDS. Acta Endocrinol. (1969) 61:307–19. doi: 10.1530/acta.0.0610307

141. Baker BL, Jaffe RB. The cell type genes in the adenohypophysis of the human fetus as observed with immunocytochemistry. Am J Anatomy. (1975) 143:137–61. doi: 10.1023/A:1010430202

142. Yen S. Endocrine-Metabolic Adaptations in Pregnancy. Reproductive Endocrinology. Philadelphia: WB Saunders. (1991). p.936–81.

143. Smith R. Parturition. N Engl J Med. (2007) 356:271–83. doi: 10.1056/NEJMra061360

144. Rehman KS, Sirianni R, Parker CR, Jr., Rainey WE, Carr BR. The evolution of mammalian pregnancy: turning a foe into a friend. Trends Cogn Sci. (2017) 21:742–54. doi: 10.1016/j.tics.2017.06.004

145. Zettergren A, Jonsson L, Johansson D, Melke J, Lundström S, Anckarsäter H, et al. Associations between polymorphisms in sex steroid related genes and autistic spectrum disorder? A systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. (2017) 56:664–74. doi: 10.1016/j.jaac.2017.03.013

146. Arnold AP, Gorski RA. Gonadal steroid induction of structural sex differences in the central nervous system. Annu Rev Neurosci. (1984) 7:413–42. doi: 10.1146/annurev.ne.07.030184.002213

147. McCarthy MM. Estradiol and the developing brain. Physiol Rev. (2008) 88:91–124. doi: 10.1152/physrev.00010.2007

148. McPartland J, Philbin EA, Fraser EJ, Coats JK, Tolkuhn J, Honda S-I, et al. The fetal placental hypothalamic–pituitary–adrenal (HPA) axis, parturition and postnatal health. Mol Cell Endocrinol. (2019) 572(Pt 1):31–44. doi: 10.1016/j.mce.2018.10.008

149. Bayati P, Malekzadeh R, W-quote. Co-19 aND c-18 sTEROIDS. Acta Endocrinol. (1969) 61:307–19. doi: 10.1530/acta.0.0610307

150. McNutt R, Zittergretten A, Jonsson L, Johansson D, Melke J, Lundström S, Anckarsäter H, et al. Associations between polymorphisms in sex steroid related genes and autistic-like traits. Psychoneuroendocrinology. (2013) 38:2575–84. doi: 10.1016/j.psyneuen.2013.06.004

151. Zito G, Tommasi S, Nappi A, Belletti M, Malaguti M. Maternal asthma is associated with reduced female fetal growth. Crit Care Med. (2003) 168:1317–23. doi: 10.1016/S0385-8146(03)002213

152. Worsham et al. Prenatal Hormone Milieu in ASD
221. Van De Beek C, Thijssen JHH, Cohen-Kettenis PT, Van Goozen SHM, Rodeck CH, Gill D, Rosenberg DA, Collins WP. Testosterone levels in
220. Scott HM, Mason JI, Sharpe RM. Steroidogenesis in the fetal testis and its
230. Worsham et al. Prenatal Hormone Milieu in ASD

227. Ramón y Cajal CL, Martínez RO. Defecation in utero: a physiological fetal
225. Whitehouse AJ, Mattes E, Maybery MT, Dissanayake C, Sawyer M, Jones RM, et al. No relationship between prenatal androgen exposure and autistic
traits: convergent evidence from studies of children with congenital
adrenal hyperplasia and of amniotic testosterone concentrations in
typically developing children. J Child Psych Psychiatry. (2016) 57:1455–62. doi: 10.1111/jcpp.12596

219. Baron-Cohen S, Tsopmanidis A, Auyeung B, Norgaard-Pedersen B, Hougaard DM, Abballah M, et al. Foetal oestrogens and autism. Mol Psychiatry. (2020) 25:2970–8. doi: 10.1038/s41380-019-0454-9

222. Park BY, Lee BK, Burstyn I, Tabb LP, Keelan JA, Whitehouse AJ, et al. In vitro testosterone biosynthesis in the human fetal testis. J Clin Endocrinol Metab. (1989) 69:204–8. doi: 10.1210/jcem-69-1-204

231. Clements JA, Reyes FI, Winter JS, Faiman C. Studies on human
adenylate cyclase activity in the early human fetal testis appear to be
typically developing children. Mol Autism. (2015) 7:17. doi: 10.1186/s11689-015-9114-9

224. Jamnadass ESL, Keelan JA, Hollier LP, Hickey M, Maybery MT, Whitehouse AJ, et al. No relationship between prenatal androgen exposure and autistic

232. Ahluwalia B, Williams J, Verma P. In vitro testosterone biosynthesis
in the human fetal testis. J Clin Endocrinol Metab. (1977) 44:963–7. doi: 10.1210/jcem-44-5-963

237. Dugoff L. First- and second-trimester maternal serum markers for
aneuploidy and adverse obstetric outcomes. Obstet Gynecol. (2010) 115:1052–61. doi: 10.1097/AOG.0b013e3181d93da

239. Smail PJ, RFI, Winter JD, Faiman C. Elevated second trimester human chorionic
gonadotropin levels in

241. Melau C, Nielsen JE, Frederiksen H, Kilcoyne K, Perlmán S, Visser WE, Hofman A, et al. Reference ranges and determinants of total
hCG levels during pregnancy: the generation r study. Eur J Epidemiol. (2015) 30:1057–66. doi: 10.1007/s10654-015-0039-0

242. Reyes FI, Winter JD, Faiman C. Studies on human sexual development. I. Fetal Gonadal and Adrenal Sex Steroids. J Clin Endocrinol Metab. (1973) 37:74–8. doi: 10.1210/jcem-37-1-74

235. Tal J, Kaplan M, Sharf M, Barnea ER. Stress-related hormones affect human
sexual development. III. Fetal pituitary and serum, and amniotic fluid. Arch Gynecol Obstet. (1973) 201:381–401

244. Cole LA. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol. (2010) 8:102. doi: 10.1186/1477-7827-8-102

245. Korevaar TIM, Steegers EA, de Rijke YB, Schalkwijk-Gerritsen MM, Visser WE, Hofman A, et al. Reference ranges and determinants of total
diagnostic and screening markers from prenatal screening in california. J Aut Dev Disord. (2016) 30:883–925. doi: 10.1007/s10654-015-0039-0

246. Kayisli UA, Selam B, Guzeloglu-Kayisli O, Demir R, Arici A. Human
chorionic gonadotropin contributes to maternal immunotolerance and
dendritomal apoptosis by regulating fas-Fasl ligand system. J Immunol. (2003) 171:2305–13. doi: 10.4049/jimmunol.171.5.2305

247. Windham GC, Lyall K, Anderson M, Khairraz M. Autism spectrum disorder risk in relation to maternal mid-Pregnancy serum hormone and protein
markers from prenatal screening in california. J Autism Dev Disorders. (2016) 46:257–7. doi: 10.3390/jamdd7500257

248. Onderoglu LS, Kabukçu A. Elevated second trimester human chorionic
gonadotropin level associated with adverse pregnancy outcome. Int J Gynaecol Obstet. (1997) 56:245–9. doi: 10.1016/s0021-7292(96)02830-5

249. Olsen RN, Woelkers D, Dumonso-Ru S, Lacourserie D. Abnormal second-trimester serum analytes are more predictive of preterm preeclampsia. Am J Obstet Gynecol. (2012) 207:222.e1–7. doi: 10.1016/j.ajog.2012.06.006

250. Benn PA, Horne D, Bridgitt S, Rodis JF, Clive JM. Elevated second-trimester maternal serum hCG alone or in combination with elevated alpha-fetoprotein. Obstet Gynecol. (1996) 87:217–22. doi: 10.1016/0029-7844(95)00390-8

251. Weinsten KD, Owen J, Boots LR, DuBard MB. Elevated second-trimester human chorionic gonadotropin levels in
association with poor pregnancy outcome. Am J Obstet Gynecol. (1994) 171:1038–41. doi: 10.1016/0002-9378(94)0030-2

252. Tal J, Kaplan M, Sharf M, Barnea ER. Stress-related hormones affect human
chorionic gonadotropin secretion from the early human placenta in vitro. Hum Reprod. (1991) 6:766–9. doi: 10.1093/oxfordjournals.humrep.a137425

253. Serón-Ferré M, Lawrence CC, Jaffe RB. Role of hCG in regulation of the fetal zone of the human fetal adrenal gland. J Clin Endocrinol Metab. (1978) 37:74–8. doi: 10.1210/jcem-37-2-74

254. Hammond GL. Plasma steroid-binding proteins: primary gatekeepers of steroid hormone action. J Endocr. (2016) 230:R13–R25. doi: 10.1530/JEO-16-0070
271. van Abeelen AFM, de Rooij SR, Osmond C, Painter RC, Misra DP, Salafia CM, Miller RK, Charles AK. Non-Linear and J Physiol. 2015; 21:2592.
272. Tarrade A, Panchenko P, Junien C, Gabory A. Placental contribution to nutritional programming of health and diseases: epigenetics and sexual dimorphism. J Exp Biol. (2015) 218:30–8. doi: 10.1242/jeb.110320
273. Sood R, Zehnder JL, Druzin ML, Brown PO. Gene expression patterns in human placenta. Proc Natl Acad Sci. (2006) 103:5478–83. doi: 10.1073/pnas.0508035103
274. Baulieu EE, Dray F. Conversion of h3-Dehydroisoandrosterone (3β-Hydroxy-Δ5-androsten-17-one) sulfate to h3-Estrogens in normal pregnant women. J Clin Endocrinol Metab. (1963) 23:1298–301. doi: 10.1210/jcem-23-12-1298
275. Pecks U, Rath W, Kleine-Eggebrecth N, Maass N, Voigt F, Goeccke T, et al. Maternal serum lipid, estradiol, and progesterone levels in pregnancy, and the impact of placental and hepatic pathologies. Geburtshilfe Frauenhe. (2016) 76:999–808. doi: 10.1055/s-0042-170708
276. Sandman CA. Fetal exposure to placental corticotropic-releasing hormone (pCRH) programs developmental trajectories. Peptides. (2015) 72:145–53. doi: 10.1016/j.peptides.2015.03.020
277. Thomson M. The physiological roles of placental corticotropin releasing hormone in pregnancy and childbirth. J Physiol Biochem. (2013) 69:559–73. doi: 10.1007/s13105-012-0227-2
278. Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm Behav. (2012) 62:263–71. doi: 10.1016/j.yhbeh.2012.02.023
279. Magnes RR, Rosenfeld CR. Local and systemic estradiol-17 beta: effects on uterine and systemic vasodilation. Am J Physiol. (1989) 256(4 Pt 1):E536–42. doi: 10.1152/ajpendo.1989.256.4.E536
280. Mandalá M. Influence of estrogens on uterine vascular adaptation in normal and preeclamptic pregnancies. Int J Mol Sci. (2020) 21:2592. doi: 10.3390/ijms21072392
281. Palmer SK, Zamudio S, Coffin C, Parker S, Stamm E, Moore LG. Quantitative estimation of human uterine artery blood flow and pelvic blood flow redistribution in pregnancy. Obstet Gynecol. (1992) 80:1000–6.
282. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. (1971) 284:878–81. doi: 10.1056/NEJM197104222841604
283. Giusti RM, Iwamoto K, Hatch EE. Diethylstilbestrol revisited: a review of the long-term health effects. Ann Intern Med. (1995) 122:778–88. doi: 10.7326/0003-4819-122-10-199505150-00008
284. Kioumourtzoglou MA, Coull BA, O’Reilly É J, Ascherio A, Weisskopf MG. Association of exposure to diethylstilbestrol during pregnancy with multigenerational neurodevelopmental deficits. JAMA Pediatr. (2018) 172:670–7. doi: 10.1001/jamapediatrics.2018.0727

Conflict of Interest: DB was a consultant for BioMarin Pharmaceutical and Encoded Therapeutics and serves as a consultant and scientific advisory board member for Taysha GTX. The content of this manuscript does not overlap with her work for these companies.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Worsham, Dalton and Bilder. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.